PMOS, the new name for PCOS: the scan you don't need

Clinical Rounds, the GPAtlas podcast. Women's Health. 22 minutes. Published 31 August 2026. Free to listen.

Clinical source: our own Ocean article "Polycystic Ovary Syndrome (PCOS)", last reviewed 11 June 2026.

Transcript

Sarah: Hello, and welcome to GPAtlas Clinical Rounds. I'm Sarah, and this is the podcast where we take one thing you'll genuinely see this week and work out what to do with it.

Ben: And I'm Ben. Today, the condition you know as polycystic ovary syndrome, which has just been renamed. It is now polyendocrine metabolic ovarian syndrome, PMOS. And there's a scan that goes with it that a lot of us are still ordering and shouldn't be.

Sarah: A fifteen year old comes in with her mother. Her periods started two years ago and they're all over the place, sometimes two months apart. She's got acne and some hair on her chin that she's very unhappy about. And her mother has done her research and would like an ultrasound, because a friend's daughter had one and it showed cysts. And the honest answer is that the scan is the one thing I definitely should not do.

Ben: Four things. What the new name is and what it does and doesn't mean for your coding on Monday. Why ultrasound has dropped out of the adult diagnosis. Why it's actively wrong in an adolescent. And the parts of the long-term care that are ours.

Ben: Before the scan, the name, because it's the thing you'll have seen and it takes a minute to settle. Our article says the condition has recently been renamed by international consensus, announced at the European Congress of Endocrinology in May this year, to polyendocrine metabolic ovarian syndrome, PMOS. And the reasoning is in the name: it reflects the multisystem endocrine and metabolic nature of it, rather than describing it as a disorder of ovarian cysts, which was always a slightly misleading way to think about it.

Sarah: And then the practical half, which our article is careful about and so are we. It uses the old term throughout, deliberately, because that is still the term in current UK clinical systems, in coding, and in patient materials. So PMOS is the incoming name. It is not yet the one to type into your system, and it isn't yet the word most patients will recognise.

Sarah: So you can say the new name and still code the old one. Both are correct today.

Sarah: So, adults first. The diagnosis is two out of three: irregular cycles, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on scan. And what's changed is that our article says the twenty twenty-three guideline confirms irregular cycles plus hyperandrogenism is sufficient in adults, and that ultrasound adds nothing and risks over-diagnosis.

Ben: So in an adult woman who already has irregular cycles and, say, hirsutism, you have your two criteria. The scan can only either confirm what you already know, or find morphology in someone who'd have been diagnosed anyway. It cannot change the answer, and it can add a label to someone who doesn't need one.

Sarah: And if a scan does get done, the threshold has moved and it's worth knowing, because a lot of reports still quote the old one. It's twenty or more follicles in at least one ovary, not twelve. So a report saying fourteen follicles is not polycystic ovarian morphology by current criteria, even though it sounds like it.

Ben: Two out of three. And in adults the scan is not one of them.

Sarah: Now the adolescent, which is our patient, and where it goes from unnecessary to actively misleading. In adolescents, within eight years of menarche, both hyperandrogenism and irregular cycles are required. Not two of three. Both of those two.

Ben: And the scan is out entirely. Our article says multi-follicular ovaries are a normal finding in the years after menarche, so ultrasound, and AMH, cannot separate PCOS from normal puberty, and are not recommended within roughly eight years of menarche.

Sarah: Which is exactly why the mother's request is the wrong thing to grant. Her daughter is two years post-menarche. A scan would very likely show multi-follicular ovaries, because that's normal at fifteen, and the family would leave with a diagnosis built on a normal finding. That label then follows her into every consultation for decades.

Ben: And there's a category for the ones who don't meet the criteria, which is more useful than a yes or no. Those with features who fall short are at increased risk, and should be reassessed by eight years post-menarche, particularly if the features predate the combined pill, persist, or accompany significant adolescent weight gain.

Sarah: So what I can offer the mother is better than a scan, and I have to sell it as such. Not, no scan. But: at fifteen a scan can't tell us anything true, so what we'll do instead is treat the symptoms that are bothering her now, and we'll look at this again properly rather than labelling her today. That's a plan with a review date, not a refusal.

Ben: Two years post-menarche, the scan cannot tell you anything true.

Sarah: Two blood-test points. The one to stop ordering: the LH to FSH ratio is no longer diagnostic. It persists in a lot of local request forms and in a lot of our memories, and it doesn't make the diagnosis.

Ben: And the one that must not be missed. A total testosterone above five nanomoles per litre, or more than twice the upper limit of the local reference range, means excluding an androgen-secreting tumour and congenital adrenal hyperplasia, with specialist referral. That's the number that turns a routine hormonal work-up into an urgent one.

Sarah: And clinically, rapid-onset or severe hirsutism, or frank virilisation, so a deepening voice, clitoromegaly, increased muscle bulk, is a suspected androgen-secreting tumour and an urgent endocrinology or gynaecology referral. The tempo is the clue. PCOS comes on gradually over years. Something that's changed over months is a different problem.

Ben: Above five, or double the local range. That is a referral.

Sarah: Management, and the first-line is not a drug. Lifestyle is first-line for everyone, and our article gives a figure that makes it worth saying properly: even a five to ten per cent weight loss can restore ovulation and improve the metabolic and androgenic features. Restore ovulation. That's a concrete, meaningful outcome, not a general health platitude.

Ben: With a dose: at least a hundred and fifty minutes a week of moderate activity, or seventy- five vigorous, plus resistance work. And a caution our article includes that I think matters in this group especially: do not dismiss an eating disorder on the basis of weight. A weight-focused consultation with a young woman who has body image distress is a place where that can be missed.

Sarah: And the endometrial protection point, which is the bit of PCOS care most likely to be forgotten because nobody's symptomatic. If she's oligomenorrhoeic or amenorrhoeic, you induce a withdrawal bleed at least every three to four months. That's the interval.

Ben: And attached to it, a safety-netting rule: investigate persistent intermenstrual or breakthrough bleeding, or amenorrhoea with abnormal bleeding, with a transvaginal ultrasound with or without an endometrial biopsy, and do not dismiss it as just PCOS. So the woman with a PCOS label who starts bleeding oddly needs investigating, and the label is the thing most likely to stop that happening.

Sarah: A bleed every three to four months. And abnormal bleeding is never just PCOS.

Sarah: On the drugs, two that come up. Co-cyprindiol, for the hirsutism and acne, has rules that get missed. It carries a one and a half to two times higher VTE risk than levonorgestrel pills, it must not be combined with another hormonal contraceptive, because that doubles the oestrogen exposure, and it should be stopped three to four months after the symptoms are controlled, which is MHRA advice.

Ben: That combining error is the dangerous one, and it's easy to make. Someone's on it for their skin, and a different clinician adds a contraceptive pill because they need contraception, and nobody registers that the first one is already a combined hormonal contraceptive.

Sarah: And eflornithine cream, for facial hair, has a review point: review at four months and stop if it's ineffective, because the hair regrows within about eight weeks of stopping anyway. So it's a four-month trial, not an indefinite prescription.

Ben: And for fertility, letrozole is now first-line for ovulation induction, off-label and specialist-supervised, preferred over clomifene for higher live-birth rates. So if she asks in ten years, the answer has changed from what most of us learned.

Sarah: Never two combined hormonal contraceptives at once.

Sarah: Then the long game, which is where our article says something new. Offer a structured annual review, which is recommended in NICE's draft guideline: symptoms, current medication, and the long-term risks of type 2 diabetes, cardiovascular disease and mental health problems, while lifestyle change can still help.

Ben: And two reassurances worth giving explicitly, because patients have usually read the opposite. PCOS does not increase breast or ovarian cancer risk. And it carries no DVLA notification and no driving restriction. Both of those come up and both are easy to answer with certainty.

Sarah: And one funding reality to be straight about rather than vague: NICE's draft guideline does not recommend laser or light-based hair reduction on cost-effectiveness grounds, so it isn't routinely NHS-funded. Better to say that plainly than to write a referral that gets declined.

Sarah: Coming back to the name, because in the room it lands as a question rather than a fact. A patient who has read about the rename is not wrong, and a colleague who has never heard of it is not behind. It genuinely has changed, and it genuinely has not reached the systems, and both of those are true at once. That's an awkward thing to hold, and it's worth saying plainly rather than picking a side.

Ben: And there's more coming, because NICE's first UK guideline on this is currently in draft, with the final expected in December. So the terminology and the guidance are both moving at the same time, which is unusual, and it means anything you tell a patient today about what it will be called has a shelf life.

Sarah: She is not wrong and your colleague is not behind. Both are true.

Ben: No increase in breast or ovarian cancer. Say that one out loud.

Sarah: I want to spend a bit longer on the conversation with the mother, because refusing a scan to a worried parent is genuinely difficult and doing it badly costs you the consultation.

Sarah: What she's actually asking for isn't an ultrasound. She's asking for certainty, and for someone to take her daughter seriously. And a scan is the most concrete-looking way she can imagine getting both. So if I just say no, she hears that I'm not taking it seriously, and the ultrasound becomes the thing we're arguing about instead of her daughter's skin and periods.

Sarah: So I try to give her the seriousness first and the scan question second. Her cycles are irregular and she has hirsutism, and both of those are real and both are treatable, and we're going to treat them today. And then: the reason I'm not scanning is that at two years post-menarche the scan would very likely look polycystic in a girl with completely normal ovaries, so it can't tell us apart from normal.

Ben: And that's the accurate framing, which our article supports directly: multi-follicular ovaries are a normal finding in the years after menarche, so ultrasound and AMH cannot separate PCOS from normal puberty. It isn't that the scan is unnecessary. It's that its result would be uninterpretable, which is a stronger and more honest position.

Sarah: And then I give her the follow-up, because otherwise it sounds like a fob-off. There's a reassessment point, by eight years post-menarche, and there's an in-between category for girls with features who don't yet meet criteria, who are described as at increased risk and are meant to be reassessed. So her daughter isn't being sent away undiagnosed. She's being placed on a pathway with a review date.

Ben: The scan is not unnecessary. Its result would be uninterpretable.

Sarah: And one thing about the long-term framing that I think we get wrong with teenagers particularly. It's easy, once PCOS is on the table, to make the whole consultation about future diabetes and cardiovascular risk and fertility, because that's what the guidance emphasises and it's what we've read.

Sarah: But a fifteen year old came in about her chin and her periods. Those are the things ruining her week. And our article's own first-line, lifestyle, with the specific figure that five to ten per cent weight loss can restore ovulation, is far more persuasive when it's connected to the thing she cares about than when it's connected to a risk she'll face at fifty.

Ben: She came about her chin. Start there.

Ben: Two things worth adding on the diagnostic criteria, because they get asked about. The first is ethnicity. Our article notes when setting out the two-out-of-three rule that the condition may be more prevalent, and the criteria may differ, in women of Black, Asian or mixed ethnicity. So the thresholds are not uniformly validated across populations, and that's worth holding lightly rather than applying mechanically.

Ben: The second is the scope of who this applies to, which our article states inclusively: girls aged over ten, women, and trans men and non-binary people assigned female at birth, excluding those on, or who have had, gender-affirming hormone therapy or surgery. That exclusion matters clinically, because exogenous hormones make both the cycle criterion and the androgen criterion uninterpretable.

Ben: And on scale, it's worth knowing it affects around one in eight women, which is high enough that most of us have a substantial number on our lists, many of them undiagnosed and many of them carrying a diagnosis that was made on an ultrasound they should never have had.

Ben: Which is really the two failure modes of this condition side by side. Under-diagnosis in the woman whose irregular cycles and hirsutism were never put together. And over-diagnosis in the teenager who got a scan. Both are common, and the second one is the one we create ourselves.

Sarah: One in eight. Under-diagnosed in adults, over-diagnosed in teenagers.

Ben: Exam corner. A fifteen year old, two years post-menarche, has irregular cycles and hirsutism. Her mother requests a pelvic ultrasound. What is the most appropriate response? A, arrange the ultrasound to confirm the diagnosis. B, arrange an AMH level instead. C, explain that ultrasound and AMH cannot distinguish PCOS from normal puberty at this stage, treat symptoms, and plan reassessment. Or D, diagnose PCOS now on her two features and start the combined pill.

Ben: It's C. Within about eight years of menarche, multi-follicular ovaries are a normal finding, so neither ultrasound nor AMH can separate PCOS from normal puberty, and neither is recommended. A and B both risk a diagnosis built on a normal finding. D is closer, because in adolescents you do need both hyperandrogenism and irregular cycles and she has both, but the article's framing is caution where features are present, with reassessment by eight years post-menarche, so committing her to a lifelong label at fifteen is the thing to avoid. Treat the acne and the hirsutism, and review.

Sarah: So. Three things for Monday. One. In adults, irregular cycles plus hyperandrogenism is enough, and the scan adds nothing. Two. In the first eight years after menarche, don't scan and don't send an AMH, because normal puberty looks exactly like this. And three. A woman with a PCOS label who develops abnormal bleeding gets investigated, because the label is the thing most likely to stop you looking.

Sarah: One thing to reflect on, if you're logging this. Think about how you'd say no to that mother, in a way that sounds like better care rather than less. The full transcript and the references are on the episode page. Ben and I are synthetic voices. The medicine isn't. See you next week.

More from Clinical Rounds

Every episode of Clinical Rounds, free to listen with a full transcript.